This site requires that JavaScript is enabled in order to validate data and display certain elements on the page. Please re-enable JavaScript, or contact your IT department to help you in doing so.
The IMS user group event takes place on Thursday 21st October. The event will take place online using Microsoft Teams, more information and registration details are available on the event web page.
The Integrated Monitoring System (IMS) annual data report presents an overview of all activity recorded in IMS for the 2020-21 financial year together with tables showing year on year change to the previous full year.
The annual report for the Integrated Monitoring System (IMS) details all activity across Cheshire and Merseyside for individuals in contact with drug or alcohol treatment/low threshold or syringe exchange services.
The IMS Drug Related Deaths annual conference will take place on Thursday 2nd December 2021, click for more details.
Our NSP activity reports now include a monthly and weekly activity breakdown to track the impact of COVID19 restrictions on NSP service provision.
Our quarterly report which shows your IMS data in three distinct cohort groups, includes activity for the first quarter of the 2021-22 year and all activity for the last four quarters. Available on the 'Quarterly Reports' tab.
Minimum Standards for Needle Syringe Programme (NSP) Across Humankind. These minimum standards for used in conjunction with locally commissioned service level arrangements (e.g. for community pharmacy provision) documents where appropriate.
Posted: 28 Sept 2021
Data tables and commentary for the unlinked anonymous monitoring surveys of infections and risk among people who inject drugs (PWID).
Posted: 28 July 2021
The drug strategy sets out how the government and its partners, at local, national and international levels, will take new action to tackle drug misuse and the harms it causes.
Posted: 14 July 2017
RSPH are calling for measures aimed at moving UK drugs strategy away from a predominantly criminal justice approach towards one based on public health and harm reduction. Their report 'Taking a New Line on Drugs' proposes a new approach to UK drug policy, featuring opinion from PHI director Jim McVeigh.
Posted: 16 June 2016
Naloxone is the emergency antidote for overdoses caused by heroin and other opiates/opioids (such as methadone and morphine). The main life-threatening effect of heroin and other opiates is to slow down and stop breathing. Naloxone blocks this effect and reverses the breathing difficulties. On the 1 October 2015, new regulations came into force, which allows for widening of the availability of naloxone.
Posted: 10 November 2015
The National Institute for Health and Care Excellence (NICE) has issued three new quality standards (QS82, QS83 & QS84) to encourage healthy living and reduce harm from smoking, alcohol and physical inactivity.
Posted: March 2015
PHE briefing regarding legal changes allowing the provision of foil by drug treatment and needle syringe exchange providers.
Posted: August 2014
NICE public health guidance update(PH52) containing recommendations on needle and syringe programmes
Posted: April 2014
Best practice guidance from the National Treatment Agency (NTA) for commissioners and providers of pharmaceutical services for drug users.
Posted: February 2006
